Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.
Jinjin ZhuJia ChenPublished in: Molecular biology reports (2022)
We reviewed the recently published literatures on immune checkpoint (IC) and targeted agents in relapse and GVHD after allogeneic HSCT RESULTS: Emerging data suggest that IC is an attractive target to modulate immune responses, and accumulating evidences of IC-targeted agents have been published for the treatment of malignancies and autoimmune disorders. The unique mechanism of IC-targeted agents, which affects the immune homeostasis of the transplant recipient by modulating alloreactivity, minimizes the risk of organ toxicity and immunosuppression associated with conventional therapy CONCLUSION: There is an increase in literature reporting the application of immune checkpoint-targeted agents in HSCT settings, and an overview will benefit further exploration in this field.
Keyphrases
- cancer therapy
- immune response
- bone marrow
- randomized controlled trial
- multiple sclerosis
- oxidative stress
- hematopoietic stem cell
- stem cell transplantation
- emergency department
- acute myeloid leukemia
- dendritic cells
- low dose
- acute lymphoblastic leukemia
- toll like receptor
- electronic health record
- big data
- combination therapy
- inflammatory response
- deep learning
- allogeneic hematopoietic stem cell transplantation
- meta analyses